Risk of severe COVID-19 in patients treated with IBD medications : a French nationwide study
© 2021 John Wiley & Sons Ltd..
BACKGROUND: Recently, the SECURE-IBD study, based on a physician-reported registry, suggested that thiopurines, either alone or combined with anti-TNF, may increase risk of severe COVID-19.
AIMS: To compare the risk of severe COVID-19 according to IBD medications in a large and unselected population.
METHODS: Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID-19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio-demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities.
RESULTS: Among 268 185 IBD patients, 600 were hospitalised for COVID-19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID-19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66-1.35) for immunomodulator monotherapy, 1.05 (0.80-1.38) for anti-TNF monotherapy, 0.80 (0.38-1.69) for anti-TNF combination therapy, 1.06 (0.55-2.05) for vedolizumab and 1.25 (0.64-2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID-19 did not differ according to IBD treatment.
CONCLUSIONS: Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID-19 infection.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2021 Jul;54(2):208-209. - PMID 34170535 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 54(2021), 2 vom: 10. Juli, Seite 160-166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meyer, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunologic Factors |
|---|
| Anmerkungen: |
Date Completed 30.06.2021 Date Revised 30.06.2021 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2021 Jul;54(2):208-209. - PMID 34170535 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.16410 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326580417 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326580417 | ||
| 003 | DE-627 | ||
| 005 | 20231225194912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.16410 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326580417 | ||
| 035 | |a (NLM)34110040 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meyer, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of severe COVID-19 in patients treated with IBD medications |b a French nationwide study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2021 | ||
| 500 | |a Date Revised 30.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2021 Jul;54(2):208-209. - PMID 34170535 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Recently, the SECURE-IBD study, based on a physician-reported registry, suggested that thiopurines, either alone or combined with anti-TNF, may increase risk of severe COVID-19 | ||
| 520 | |a AIMS: To compare the risk of severe COVID-19 according to IBD medications in a large and unselected population | ||
| 520 | |a METHODS: Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID-19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio-demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities | ||
| 520 | |a RESULTS: Among 268 185 IBD patients, 600 were hospitalised for COVID-19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID-19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66-1.35) for immunomodulator monotherapy, 1.05 (0.80-1.38) for anti-TNF monotherapy, 0.80 (0.38-1.69) for anti-TNF combination therapy, 1.06 (0.55-2.05) for vedolizumab and 1.25 (0.64-2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID-19 did not differ according to IBD treatment | ||
| 520 | |a CONCLUSIONS: Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID-19 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 700 | 1 | |a Semenzato, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Zureik, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Weill, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonnel, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Dray-Spira, Rosemary |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 54(2021), 2 vom: 10. Juli, Seite 160-166 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2021 |g number:2 |g day:10 |g month:07 |g pages:160-166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.16410 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2021 |e 2 |b 10 |c 07 |h 160-166 | ||